is mounjaro a glp 1 (tirzepatide) dual incretin agonist targeting both GLP-1 and GIP receptors. It improves glycaemic control by enhancing insulin secretion, suppressing glucagon, and delaying gastric emptying — which also leads to GLP-1 Weight Loss Myths: What

What the research supports: Semaglutide (GLP-1 medication): Clinical trials show meaningful average weight loss for many people when used with lifestyle support and medical monitoring

Together, they synergistically promote sperm quality, enhancing motility and overall fertility, making them promising therapeutic agents for managing male infertility associated with impaired sperm parameters

These symptoms are usually mild and short-lived

Borgmann D, Ciglieri E, Biglari N, Brandt C, Cremer AL, Backes H, et al

These agents are used primarily in the treatment of type 2 diabetes mellitus and obesity

Accessed at www.health.com/weight-loss-drugs-ineffective-tips-8737773